125 related articles for article (PubMed ID: 28388298)
1. NF-κB Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers.
Poma P; Labbozzetta M; D'Alessandro N; Notarbartolo M
OMICS; 2017 Apr; 21(4):225-231. PubMed ID: 28388298
[TBL] [Abstract][Full Text] [Related]
2. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
[TBL] [Abstract][Full Text] [Related]
3. Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-κB signaling in triple-negative breast cancer cells.
Raman V; Fuentes Lorenzo JL; Stashenko EE; Levy M; Levy MM; Camarillo IG
Int J Oncol; 2017 Dec; 51(6):1801-1808. PubMed ID: 29075784
[TBL] [Abstract][Full Text] [Related]
4. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway.
Pan H; Zhou W; He W; Liu X; Ding Q; Ling L; Zha X; Wang S
Int J Mol Med; 2012 Aug; 30(2):337-43. PubMed ID: 22580499
[TBL] [Abstract][Full Text] [Related]
5. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
6. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Yuan Z; Jiang H; Zhu X; Liu X; Li J
Biomed Pharmacother; 2017 May; 89():227-232. PubMed ID: 28231544
[TBL] [Abstract][Full Text] [Related]
7. Potential Therapeutic Applications of MDA-9/Syntenin-NF-κB-RKIP Loop in Human Liver Carcinoma.
Notarbartolo M; Labbozzetta M; Pojero F; D'Alessandro N; Poma P
Curr Mol Med; 2018; 18(9):630-639. PubMed ID: 30608040
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic changes and nuclear factor-κB activation, but not microRNA-224, downregulate Raf-1 kinase inhibitor protein in triple-negative breast cancer SUM 159 cells.
Labbozzetta M; Poma P; Vivona N; Gulino A; D'Alessandro N; Notarbartolo M
Oncol Lett; 2015 Dec; 10(6):3807-3815. PubMed ID: 26788213
[TBL] [Abstract][Full Text] [Related]
9. Targeting the NF-kappa B pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs.
Monks NR; Pardee AB
J Cell Biochem; 2006 May; 98(1):221-33. PubMed ID: 16408291
[TBL] [Abstract][Full Text] [Related]
10. STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer.
Kuo WY; Hwu L; Wu CY; Lee JS; Chang CW; Liu RS
Theranostics; 2017; 7(3):647-663. PubMed ID: 28255357
[TBL] [Abstract][Full Text] [Related]
11. Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone.
Jeon M; Han J; Nam SJ; Lee JE; Kim S
Chem Biol Interact; 2016 Oct; 258():126-33. PubMed ID: 27567548
[TBL] [Abstract][Full Text] [Related]
12. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
Jiang F; Li Y; Si L; Zhang Z; Li Z
Cell Biol Toxicol; 2019 Aug; 35(4):361-371. PubMed ID: 30612216
[TBL] [Abstract][Full Text] [Related]
13. Tropomodulin 1 expression driven by NF-κB enhances breast cancer growth.
Ito-Kureha T; Koshikawa N; Yamamoto M; Semba K; Yamaguchi N; Yamamoto T; Seiki M; Inoue J
Cancer Res; 2015 Jan; 75(1):62-72. PubMed ID: 25398440
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB.
Sliva D; English D; Lyons D; Lloyd FP
Biochem Biophys Res Commun; 2002 Jan; 290(1):552-7. PubMed ID: 11779207
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of NF-κB and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells.
Watanabe M; Umezawa K; Higashihara M; Horie R
Oncol Res; 2013; 21(4):173-80. PubMed ID: 24762223
[TBL] [Abstract][Full Text] [Related]
16. Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
Katsman A; Umezawa K; Bonavida B
Drug Resist Updat; 2007; 10(1-2):1-12. PubMed ID: 17306602
[TBL] [Abstract][Full Text] [Related]
17. RIP2 enhances cell survival by activation of NF-ĸB in triple negative breast cancer cells.
Jaafar R; Mnich K; Dolan S; Hillis J; Almanza A; Logue SE; Samali A; Gorman AM
Biochem Biophys Res Commun; 2018 Feb; 497(1):115-121. PubMed ID: 29421659
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
Nakajima S; Kato H; Gu L; Takahashi S; Johno H; Umezawa K; Kitamura M
J Immunol; 2013 Jun; 190(12):6559-69. PubMed ID: 23690471
[TBL] [Abstract][Full Text] [Related]
19. Ixeris dentata (Thunb. Ex Thunb.) Nakai Extract Inhibits Proliferation and Induces Apoptosis in Breast Cancer Cells through Akt/NF-κB Pathways.
Shin SA; Lee HN; Choo GS; Kim HJ; Che JH; Jung JY
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134814
[TBL] [Abstract][Full Text] [Related]
20. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Starenki DV; Namba H; Saenko VA; Ohtsuru A; Maeda S; Umezawa K; Yamashita S
Clin Cancer Res; 2004 Oct; 10(20):6821-9. PubMed ID: 15501958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
